IL-32 may also affect the course of NASH progression by enhancing the expression of IL-1, TNF-α and IL-8 through the NF-κB and the p38/MAPK pathways [140]. This evidence concerns the gene TNF and metabolic dysfunction-associated steatohepatitis.